Search | Clinical Trials Finder

Conditions: Myositis
Interventions: PF-06823859, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 45
States / cities: Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 85
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: Pleural Mesothelioma, Metastatic Pleural Effusions
Interventions: Adenoviral-mediated Interferon-beta, SCH 721015; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions: Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells; Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis, Covid19
Interventions: Not listed
Lead sponsor: St. Barnabas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Interferon β-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Active Ulcerative Colitis
Interventions: BG9418 (Interferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more

Conditions: Multiple Sclerosis
Interventions: Betaseron (Interferon beta-1b, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more

Conditions: Multiple Sclerosis
Interventions: peginterferon beta-1a, Rebif; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon beta-1b, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: RNS60 125 ml, RNS60 250 ml, Interferon beta 1a; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel; Biological · Drug
Lead sponsor: Memgen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Interferon beta-1b, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • San Diego, California + 3 more

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017, naproxen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Multiple Sclerosis Relapse
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more

Conditions: Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta; Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Healthy Volunteers
Interventions: Avonex; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions: Interferon-beta; Genetic
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Search by objective public record fields.

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Gene Therapy for Pleural Malignancies

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)